Risk for myopathy with statin therapy in high-risk patients

Archives of Internal Medicine

Volumn 163, Issue 5, 2003, Pages 553-564

  Ballantyne, Christie M ^a   Corsini, Alberto ^b   Davidson, Michael H ^c   Holdaas, Hallvard ^d   Jacobson, Terry A ^e   Leitersdorf, Eran ^f   März, Winfried ^g   Reckless, John P D ^h   Stein, Evan A ⁱ  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^g UNIVERSITY OF GRAZ   (Austria)

^h ROYAL UNITED HOSPITAL   (United Kingdom)

ⁱ Pharmaceutical Product Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MYOPATHY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS;

ANTILIPEMIC AGENTS; CALCIUM CHANNEL BLOCKERS; CORONARY DISEASE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE AGENTS; MUSCULAR DISEASES; RISK FACTORS;

EID: 0037429617     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.5.553     Document Type: Review

References (128)

1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
3. Serruys PWJC, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215-3222.
4. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36:288-295.
5. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis [letter]. N Engl J Med. 2002;346:539-540.
6. SoRelle R. Baycol withdrawn from market. Circulation, 2001;104:E9015-E9016.
7. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2:205-207.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
9. Wood D, de Backer G, Faergeman O, et al, for the Second Joint Task Force of European and Other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Eur Heart J. 1998;19:1434-1503.
10. Moghadasian MH, Mancini GB, Frolich JJ. Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. Expert Opin Pharmacother. 2000;1:683-695.
11. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22:441-457.
12. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 2000;23:197-213.
13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
14. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
15. Sacks FM, Pfeffer MA, Moye LA, et al, for the CARE Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
16. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
17. Downs JR, Clearfield M, Weis S, et al, for the Air Force/Texas Coronary Atherosclerosis Prevention Study Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
18. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors. Arch Intern Med. 2000;150:2273-2280.
19. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207-213.
20. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001;35:1096-1107.
21. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatingemfibrozil combination therapy. JAMA. 1990;264:71-75.
22. Poels PJE, Gabreëls FJM. Rhabdomyolysis: a review of the literature. Clin Neurol Neurosurg. 1993;95:175-192.
23. Hamilton-Craig I. Statin-associated myopathy. Med J Aust. 2001;175:486-489.
24. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35:908-917.
25. Walker JF. HMG CoA reductase inhibitors: current clinical experience. Drugs. 1988;36(suppl 3):83-86.
26. Kogan AD, Orenstein S. Lovastatin-induced acute rhabdomyolysis. Postgrad Med J. 1990;66:294-296.
27. Deslypere JP, Vermeulen A. Rhabdomyolysis and simvastatin [letter]. Ann Intern Med. 1991;114:342.
28. Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med. 1991;154:213-215.
29. Berland Y, Vacher Coponat H, Durand C, Baz M, Laugier R, Musso JL. Rhabdomyolysis with simvastatin use [letter]. Nephron. 1991;57:365-366.
30. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA. 1988;260:239-241.
31. Baycol Product Information, 1999 [package insert]. Pittsburgh, Pa: Bayer Corporation; 2000.
32. Bruno-Joyce J, Dugas JM, MacCausland OE. Cerivastatin and gemfibrozil-associated rhabdomyolysis. Ann Pharmacother. 2001;35:1016-1019.
33. Lau TK, Leachman DR, Lufschanowski R. Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case. Tex Heart Inst J. 2001;28:142-145.
34. Alexandridis G, Pappas GA, Elisaf MS. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med. 2000;109:261-262.
35. Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Lopez-Lirola A, Rodriguez-Rodriguez E, Santolaria-Fernandez F. Acute rhabdomyolysis associated with cerivastatin therapy. Arch Intern Med. 2001;161:893.
36. Insull W Jr, Isaacsohn J, Kwiterovich P, et al, for the Cerivastatin Study Group. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. J Int Med Res. 2000;28:47-68.
37. Dujovne CA, Chremos AN, Pool JL, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results, IV: additional perspectives on the tolerability of lovastatin. Am J Med. 1991;91:25S-30S.
38. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994;74:667-673.
39. Benghozi, R, Bortolini M, Jia Y, Isaacsohn JL, Troendle AJ, Gonansun L. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol. 2002;89:231-233.
40. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996;156:2085-2092.
41. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J. 1999;20:725-741.
42. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;136:161-172.
43. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413-428.
44. Joshi HN, Fakes MG, Serajuddin ATM. Differentiation of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors by their relative lipophilicity. Pharm Pharmacol Commun. 1999;5:269-271.
45. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 1996;31:348-371.
46. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet 1997;32:403-425.
47. Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol. 1996;36:728-731.
48. Yang BB, Hounslow NJ, Sedman AJ, Forgue ST. Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine. J Clin Pharmacol. 1996;36:356-360.
49. Christians U. Combination of pravastatin and cyclosporin in transplant patients. Clin Pharmacokinet. 1997;32:173-174.
50. Siekmeier R, Lattke P, Mix C, Park JW, Jaross W. Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. J Cardiovasc Pharmacol Ther. 2001;6:137-145.
51. Sabia H, Prasad P, Smith HT, Stoltz RR, Rothenberg P. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J Cardiovasc Pharmacol. 2001;37:502-511.
52. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62:28J-34J.
53. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40:263-281.
54. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol. 1999;39:1203-1211.
55. Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P- glycoprotein. Pharm Res. 2001;18:800-806.
56. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther. 1998;80:1-34.
57. Fischer V, Johanson L, Heitz F, et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos. 1999;27:410-416.
58. Bizzaro N, Bagolin E, Milani L, Cereser C, Finco B. Massive rhabdomyolysis and simvastatin [letter]. Clin Chem. 1992;38:1504.
59. Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000;40:91-98.
60. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens. 1993;6:375S-382S.
61. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann Intern Med. 1988;109:682-683.
62. Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000;67:267-274.
63. Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann Pharmacother. 1996;30:1399-1402.
64. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000;56:225-229.
65. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 1988;318:47-48.
66. Rodriguez JA, Crespo-Leiro MG, Paniagua MJ, et al. Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine. Transplant Proc. 1999;31:2522-2523.
67. Kusus M, Stapleton DD, Lertora JJ, Simon EE, Dreisbach AW. Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci. 2000;320:394-397.
68. Stirling CM, Isles CG. Rhabdomyolysis due to simvastatin in atransplant patient: are some statins safer than others? Nephrol Dial Transplant. 2001;16:873-874.
69. Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother. 1999;33:1176-1179.
70. Rodriguez ML, Mora C, Navarro JF. Cerivastatin-induced rhabdomyolysis [letter]. Ann Intern Med. 2000;132:598.
71. Holdaas H, Jardine AG, Wheeler DC, et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int. 2001;60:1990-1997.
72. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 1997;62:311-321.
73. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 1993;25:2732-2734.
74. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporine. Nephron. 1993;65:410-413.
75. Ichimaru N, Takahara S, Kokado Y, et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis. 2001;158:417-423.
76. Muck W, Mai I, Fritsche L, et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther. 1999;65;251-261.
77. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation. 1996;62:1559-1564.
78. Kitazawa E, Tamura N, Iwabuchi H, et al. Biotransformation of pravastatin sodium. Biochem Biophys Res Commun. 1993;192:597-602.
79. Smith PF, Eydelloth RS, Grossman SJ, et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther. 1991;257:1225-1235.
80. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant. 2001;16:1545-1549.
81. Aakhus S, Dahl K, Wideroe TE. Hyperlipidaemia in renal transplant patients. J Intern Med. 1996;239:407-415.
82. Ballantyne CM, Radovancevic B, Farmer JA, et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol. 1992;19:1315-1321.
83. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627.
84. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997;96:1398-1402.
85. Keogh A, MacDonald P, Kaan A, Aboyoun C, Spratt P, Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant. 2000;19:529-537.
86. Southworth MR, Mauro VF. The use of HMG-CoA reductase inhibitorsto prevent accelerated graft atherosclerosis in heart transplant patients. Ann Pharmacother. 1997;31:489-491.
87. Ballantyne CM, Bourge RC, Domalik LJ, et al. Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol.,1996:78:522-535.
88. Jardine A, Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. J Clin Pharm Ther. 1999;24:397-408.
89. Holdaas H, Fellstrom B, Holme I, et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk. 2001;8:63-71.
90. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12:565-569.
91. Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
92. Kane JP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:2717-2752.
93. Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis. 2000;150:429-436.
94. Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med. 2000;247:563-569.
95. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 2001;69:340-345.
96. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol. 1998;81:368-369.
97. Knoll RW, Ciafone R, Galen M. Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibozil. Conn Med. 1993;57:593-594.
98. Tal A, Rajeshawari M, Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J. 1997;90:546-547.
99. Oldemeyer JB, Lund RJ, Koch M, Meares AJ, Dunlay R. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. Cardiology. 2000;94:127-128.
100. van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med. 1996;240:403-404.
101. Abdul-Ghaffar NU, el-Sonbaty MR. Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy. J Clin Gastroenterol. 1995;21:340-341.
102. Davidson MH. Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions. J Cardiovasc Pharmacol Ther. 2001;6:219-229.
103. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol. 1995;76:80A-83A.
104. Fruchart JC, Brewer HB, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol. 1998;81:912-917.
105. Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol. 1998;82:82U-84U.
106. Jacobson TA, Chin MM, Fromell GJ, Jokubaitis LA, Amorosa LF. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol. 1994;74:149-154.
107. Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (+/-colestyramine/ niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol. 2000;86:1293-1298.
108. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
109. Kashyap ML, McGovern ME, Berra K, et al. Longterm safety and efficacy of a once-daily niacin/ lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89:672-678.
110. Garnett WR. Interactions with hydroxymethyl- glutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm. 1995;52:1639-1645.
111. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med. 1988;109:597-598.
112. Schmassmann-Suhijar D, Bullingham R, Gasser R, et al. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet. 1998;351:1929-1930.
113. Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P4503A4 inhibitors and simvastatin. Am J Cardiol. 1999;84:811-815.
114. Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther. 1998;64:369-377.
115. Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol. 2001;51:461-470.
116. Peces R, Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron. 2001;89:117-118.
117. Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med. 2001;94:339-341.
118. MRC/BHF Heart Protection Study (HPS) Web site. Available at: http://www.ctsu.ox.ac.uk/projects /hps.shtml. Accessed November 20, 2001.
119. Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol. 1999;83:1146.
120. Bermingham RP, Whitsitt TB, Smart ML, Nowak DP, Scalley RD. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. Am J Health Syst Pharm. 2000;57:461-464.
121. Plotkin E, Bernheim J, Ben-Chetrit S, Mor A, Korzets Z. Influenza vaccine - a possible trigger of rhabdomyolysis-induced acute renal failure due to the combined use of cerivastatin and bezafibrate. Nephrol Dial Transplant. 2000;15:740-741.
122. Tomlinson B, Lan IW. Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable? Am J Med. 2001;110:669-670.
123. Ozdemir O, Boran M, Gokce V, Uzun Y, Kocak B, Korkmaz S. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy - a case report. Angiology. 2000;51:695-697.
124. Mastroianni CM, d'Ettorre G, Forcina G, et al. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. AIDS. 2001;15:820-821.
125. Argov Z. Drug-induced myopathies. Curr Opin Neurol 2000;13:541-545.
126. Nordin C, Dahl ML, Eriksson M, Sjoberg S. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism? Lancet. 1997;350:29-30.
127. Mulder AB, van Lijf HJ, Bon MA, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther. 2001;70:546-551.
128. Goodstein RK. Dear Health Care Professional Letter: Gemfibrozil Contraindication With Baycol. Pittsburgh, Pa: Bayer Corp; December 15, 1999.